公开(公告)号：WO2016102427A1

公开(公告)日：2016-06-30

申请号：PCT/EP2015/080720

申请日：2015-12-21

Applicant: BAYER PHARMA AKTIENGESELLSCHAFT

Inventor： EIS, Knut ,  HARTUNG, Ingo ,  PETERSEN, Kirstin ,  LIENAU, Philip ,  BÖMER, Ulf

IPC: C07D487/04 ,  A61K31/5025 ,  A61P35/00 ,  A61P37/00

CPC classification number: C07D487/04 ,  A61K31/5025 ,  A61K31/5377 ,  A61K45/06

Abstract: The present invention relates to 6-hydroxybenzofuranyl- and 6-alkoxybenzofuranyl- substituted imidazopyridazine compounds of general formula (I) in which R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Abstract translation: 本发明涉及通式（I）的6-羟基苯并呋喃基 - 和6-烷氧基苯并呋喃基 - 取代的咪唑并哒嗪化合物，其中R 1和R 2如权利要求中所定义，所述化合物的制备方法可用于制备所述化合物的中间体化合物 ，涉及包含所述化合物的药物组合物和组合，以及所述化合物用于制备用于治疗或预防疾病，特别是高增殖和/或血管发生障碍的药物组合物作为唯一试剂或组合的用途 与其他活性成分。

公开(公告)号：WO2015193339A1

公开(公告)日：2015-12-23

申请号：PCT/EP2015/063527

申请日：2015-06-17

Applicant: BAYER PHARMA AKTIENGESELLSCHAFT

Inventor： GRAHAM, Keith ,  KLAR, Ulrich ,  BRIEM, Hans ,  HITCHCOCK, Marion ,  BÄRFACKER, Lars ,  EIS, Knut ,  SCHULZE, Volker ,  SIEMEISTER, Gerhard ,  BONE, Wilhelm ,  SCHRÖDER, Jens ,  HOLTON, Simon ,  LIENAU, Philip ,  TEMPEL, René ,  SONNENSCHEIN, Helmut ,  BÁLINT, Jozsef ,  GRAUBAUM, Heinz

IPC: C07D401/14 ,  C07D405/14 ,  C07D401/04 ,  C07D403/04 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/056 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D401/04 ,  A61K31/436 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/056

Abstract: Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.

Abstract translation: 作为Bub1激酶抑制剂的式（I）化合物，其制备方法及其作为药物的用途。

公开(公告)号：WO2015150449A3

公开(公告)日：2015-10-08

申请号：PCT/EP2015/057167

申请日：2015-04-01

Applicant: BAYER PHARMA AKTIENGESELLSCHAFT

Inventor： EIS, Knut ,  ACKERSTAFF, Jens ,  WAGNER, Sarah ,  BASTING, Daniel ,  GOLZ, Stefan ,  BENDER, Eckhard ,  LI, Volkhart Min-Jian ,  LIENAU, Philip ,  LIU, Ningshu ,  SIEGEL, Franziska ,  BAUSER, Marcus ,  SÜLZLE, Detlev ,  HOLTON, Simon ,  BAIRLEIN, Michaela ,  BUCHGRABER, Philipp ,  BALINT, József

IPC: C07D233/90 ,  A61K31/4164 ,  A61K31/4439 ,  C07D401/12 ,  C07D263/34 ,  A61K31/421 ,  A61K31/496 ,  C07D403/12 ,  C07D295/092 ,  C07D413/06 ,  A61K31/5377 ,  A61K31/454 ,  A61P35/00 ,  C07D491/107 ,  A61P35/02

Abstract: The present invention relates to amido-substituted azole compounds of general formula (I), in which X 1 , X 2 , R 1 , R 2 , R 4 , R 5 , R 7 and R 8 are as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

公开(公告)号：WO2013149909A1

公开(公告)日：2013-10-10

申请号：PCT/EP2013/056532

申请日：2013-03-27

Applicant: BAYER PHARMA AKTIENGESELLSCHAFT

Inventor： EIS, Knut ,  PÜHLER, Florian ,  ZORN, Ludwig ,  SCHULZE, Volker ,  SÜLZLE, Detlev ,  LIENAU, Philip ,  HÄGEBARTH, Andrea ,  PETERSEN, Kirstin ,  BÖMER, Ulf

IPC: C07D487/04 ,  A61K31/5025 ,  A61P35/00

CPC classification number: C07D405/04 ,  A61K31/5025 ,  A61K31/5377 ,  A61K45/06 ,  C07D487/04

Abstract: The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I); in which A, R1, R2, R3, R4, R5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper- proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

Abstract translation: 本发明涉及通式（I）的氨基取代的咪唑并哒嗪化合物; 其中A，R 1，R 2，R 3，R 4，R 5和n如权利要求中所定义，涉及制备所述化合物的方法，可用于制备所述化合物的中间体化合物，包含所述化合物的药物组合物和组合， 的用于制备用于治疗或预防疾病，特别是增殖性和/或血管生成障碍的疾病的药物组合物的所述化合物作为唯一的药剂或与其它活性成分组合。

公开(公告)号：WO2013050438A1

公开(公告)日：2013-04-11

申请号：PCT/EP2012/069562

申请日：2012-10-04

Applicant: BAYER PHARMA AKTIENGESELLSCHAFT ,  BAYER INTELLECTUAL PROPERTY GMBH

Inventor： HITCHCOCK, Marion ,  MENGEL, Anne ,  PÜTTER, Vera ,  SIEMEISTER, Gerhard ,  WENGNER, Antje Margret ,  BRIEM, Hans ,  EIS, Knut ,  SCHULZE, Volker ,  FERNANDEZ-MONTALVAN, Amaury Ernesto ,  PRECHTL, Stefan ,  HOLTON, Simon ,  FANGHÄNEL, Jörg ,  LIENAU, Philip ,  PREUSSE, Cornelia ,  GNOTH, Mark Jean

IPC: C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D498/04 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D498/04 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K45/06 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D413/14

Abstract: Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.

Abstract translation: 作为Bub1激酶抑制剂的式（I）化合物，其制备方法及其作为药物的用途。